Medifast Inc reports results for the quarter ended September 30 - Earnings Summary

What happened

Medifast Inc reported a quarterly adjusted loss of 19 cents per share for the quarter ended September 30, compared with a loss of 35 cents per share expected by the lone analyst. Revenue fell 19.4% to $72.05 million, beating analyst expectations of $71.30 million.

Confirmed

Global impact / market context

The smaller adjusted loss than the lone analyst expected suggests cost controls or business trends were less weak than feared, which may support the shares. However, the 19.4% revenue decline shows demand remains under pressure, limiting any improvement in profit per sale.

Analyst inference

Analysts rate the shares a hold, with two hold ratings and no buy or sell calls, compared with a buy consensus for food processing peers. The $12.00 median price target sits about 1.1% above the last close of $11.87, implying limited expected upside.

Analyst inference

What to watch

1. The mean earnings estimate of analysts rose about 43.5% over the last three months, while no earnings estimate revisions occurred in the last 30 days, suggesting forecasts have stabilized. Confirmed
2. Watch whether upcoming quarters show revenue stabilizing after the 19.4% decline, since a smaller adjusted loss helped this quarter but weaker sales could pressure future cash available. Proposed
3. Because the average rating is hold for Medifast versus buy for peers, investor positioning could stay cautious until revenue trends improve or analysts revise their earnings estimates upward. Analyst inference

Evidence

• Original source link unavailable